| Michelle R Shepherd, PMHNP-BC | |
|
4600 3rd St, Moline, IL 61265-6106 | |
| (309) 779-2031 | |
| Not Available |
| Full Name | Michelle R Shepherd |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 4600 3rd St, Moline, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114571445 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | 209019382 (Illinois) | Secondary |
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | G154523 (Iowa) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Robert Young Center For Community Mental Health | 4587600150 | 34 |
| The Robert Young Center For Community Mental Health | 4587600150 | 34 |
News Archive
Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.
According to a new study, women can accurately recall key pregnancy-related information at least 4 years later that could have important implications for their future risk of developing cardiovascular disease (CVD).
UC San Diego Sulpizio Cardiovascular Center is now offering patients with atrial fibrillation the breakthrough benefits of heat energy, or radio frequency waves, to irreversibly alter heart tissue that triggers an abnormal heart rhythm or arrhythmia.
Gene therapy research has reached a critical phase. Already practised on humans as part of strictly controlled experiments, gene therapy promises to become a widely available form of treatment for injury and disease.
› Verified 4 days ago
| Entity Name | Trinity Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033163829 PECOS PAC ID: 2264337518 Enrollment ID: O20040217000414 |
News Archive
Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.
According to a new study, women can accurately recall key pregnancy-related information at least 4 years later that could have important implications for their future risk of developing cardiovascular disease (CVD).
UC San Diego Sulpizio Cardiovascular Center is now offering patients with atrial fibrillation the breakthrough benefits of heat energy, or radio frequency waves, to irreversibly alter heart tissue that triggers an abnormal heart rhythm or arrhythmia.
Gene therapy research has reached a critical phase. Already practised on humans as part of strictly controlled experiments, gene therapy promises to become a widely available form of treatment for injury and disease.
› Verified 4 days ago
| Entity Name | The Robert Young Center For Community Mental Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730685389 PECOS PAC ID: 4587600150 Enrollment ID: O20211208003044 |
News Archive
Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.
According to a new study, women can accurately recall key pregnancy-related information at least 4 years later that could have important implications for their future risk of developing cardiovascular disease (CVD).
UC San Diego Sulpizio Cardiovascular Center is now offering patients with atrial fibrillation the breakthrough benefits of heat energy, or radio frequency waves, to irreversibly alter heart tissue that triggers an abnormal heart rhythm or arrhythmia.
Gene therapy research has reached a critical phase. Already practised on humans as part of strictly controlled experiments, gene therapy promises to become a widely available form of treatment for injury and disease.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michelle R Shepherd, PMHNP-BC 2001 Canal Shore Dr Sw, Le Claire, IA 52753-9564 Ph: () - | Michelle R Shepherd, PMHNP-BC 4600 3rd St, Moline, IL 61265-6106 Ph: (309) 779-2031 |
News Archive
Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.
According to a new study, women can accurately recall key pregnancy-related information at least 4 years later that could have important implications for their future risk of developing cardiovascular disease (CVD).
UC San Diego Sulpizio Cardiovascular Center is now offering patients with atrial fibrillation the breakthrough benefits of heat energy, or radio frequency waves, to irreversibly alter heart tissue that triggers an abnormal heart rhythm or arrhythmia.
Gene therapy research has reached a critical phase. Already practised on humans as part of strictly controlled experiments, gene therapy promises to become a widely available form of treatment for injury and disease.
› Verified 4 days ago
Cara R Brown, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1100 36th Ave, Moline, IL 61265 Phone: 309-743-6700 | |
Mary Kathleen Skafidas, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 550 30th Ave Ste 12, Moline, IL 61265 Phone: 309-762-5513 | |
Courtney Beth Legendre, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 545 Valley View Drive, Moline, IL 61265 Phone: 309-762-5560 Fax: 309-762-7351 | |
Cari Waterkotte, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 545 Valley View Dr, Moline, IL 61265 Phone: 309-762-5560 Fax: 309-277-1191 | |
Emily Schadt, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 4376 7th St, Moline, IL 61265 Phone: 309-762-0777 Fax: 309-762-0077 | |
Kristen Olin, DNP-FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4300 7th St, Moline, IL 61265 Phone: 563-762-9800 | |
Mrs. Megan Elizabeth Pikuza, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 500 John Deere Rd Ste 102, Moline, IL 61265 Phone: 309-779-4940 |